Pfizer Inc's Form 4 filing
Pyxis Oncology, Inc. (PYXS) · filed Mar 21, 2023
- Accession no.
- 0000078003-23-000050
- Filed
- Mar 21, 2023, 6:07 PM ET
- Trade date
- Mar 17, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $5.00M. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0000078003-23-000052 (Mar 23, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pfizer IncCIK 0000078003 | 10% Owner |
| Pfizer Ventures (US) LLCCIK 0001776087 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2023 | Common Stock, $0.001 par value per share | PPurchaseAcquired | +1,811,594 | $2.76 | +$4,999,999.44 | 5,952,263 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.